{"id":59760,"date":"2023-09-11T20:36:24","date_gmt":"2023-09-12T00:36:24","guid":{"rendered":"https:\/\/ifintechworld.com\/uncategorized\/crinetics-shares-surge-after-positive-hormonal-disorder-drug-trial-results\/"},"modified":"2023-09-11T20:36:27","modified_gmt":"2023-09-12T00:36:27","slug":"crinetics-shares-surge-after-positive-hormonal-disorder-drug-trial-results","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=59760","title":{"rendered":"Crinetics shares surge after “positive” hormonal disorder drug trial results"},"content":{"rendered":"
\n
\n

\u00a9 Reuters. <\/span>
\n<\/i>\n<\/div>\n

Investing.com —\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the “positive results” of trials of its experimental treatment for a rare hormonal disease.<\/p>\n

In a statement, the San Diego-based company said its oral, once-daily compound paltusotine achieved the primary and all secondary endpoints of a randomized and placebo-controlled Phase 3 study.<\/p>\n

A total of 83% of patients using paltusotine maintained growth-factor levels, versus 4% who had taken the placebo. According to three analysts cited by Reuters, about 70% of patients receiving paltusotine were expected to keep growth-factor levels steady.<\/p>\n

Participants who took the\u00a0drug saw “no severe or serious adverse events,” Crinetics added.<\/p>\n

During the study, “biochemically controlled” patients who had been given injections to treat acromegaly — a disorder where the body naturally produces too much growth hormone — were given the oral alternative. A principal investigator who was quoted by the firm noted that the transition to oral treatments from injections was “done seamlessly” and maintained “symptom control.”<\/p>\n

“We could not be more excited by the results from [the study], which further reinforce our conviction that, if approved, paltusotine could address patients\u2019 unmet need for a simple, oral, once-daily therapy,” said Crinetics Founder and Chief Executive Scott Struthers.<\/p>\n

He added that the business would look to attain regulatory approval for the drug “as quickly as possible” once a separate trial is completed early next year of acromegaly patients who are “treatment-naive” or not currency receiving any medical therapy.<\/p>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. Investing.com —\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the “positive results” of trials of its experimental treatment for a rare hormonal disease. In a statement, the San Diego-based company said its oral, once-daily compound paltusotine achieved the primary and all secondary endpoints of a […]<\/p>\n","protected":false},"author":1,"featured_media":59761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[1],"tags":[83],"class_list":["post-59760","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-uncategorized","tag-featured","post_format-post-format-video"],"yoast_head":"\nCrinetics shares surge after "positive" hormonal disorder drug trial results | iFintechWorld<\/title>\n<meta name=\"description\" content=\"\u00a9 Reuters. Investing.com --\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=59760\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crinetics shares surge after "positive" hormonal disorder drug trial results | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"\u00a9 Reuters. Investing.com --\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=59760\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-12T00:36:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-12T00:36:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/LYNXMPEE6T19U_L.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=59760#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=59760\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Crinetics shares surge after “positive” hormonal disorder drug trial results\",\"datePublished\":\"2023-09-12T00:36:24+00:00\",\"dateModified\":\"2023-09-12T00:36:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=59760\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=59760#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=59760\",\"url\":\"https:\/\/ifintechworld.com\/?p=59760\",\"name\":\"Crinetics shares surge after \\\"positive\\\" hormonal disorder drug trial results | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-09-12T00:36:24+00:00\",\"dateModified\":\"2023-09-12T00:36:27+00:00\",\"description\":\"\u00a9 Reuters. Investing.com --\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=59760#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=59760\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=59760#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crinetics shares surge after “positive” hormonal disorder drug trial results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crinetics shares surge after \"positive\" hormonal disorder drug trial results | iFintechWorld","description":"\u00a9 Reuters. Investing.com --\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=59760","og_locale":"en_US","og_type":"article","og_title":"Crinetics shares surge after \"positive\" hormonal disorder drug trial results | iFintechWorld","og_description":"\u00a9 Reuters. Investing.com --\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the","og_url":"https:\/\/ifintechworld.com\/?p=59760","og_site_name":"iFintechWorld","article_published_time":"2023-09-12T00:36:24+00:00","article_modified_time":"2023-09-12T00:36:27+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/LYNXMPEE6T19U_L.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=59760#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=59760"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Crinetics shares surge after “positive” hormonal disorder drug trial results","datePublished":"2023-09-12T00:36:24+00:00","dateModified":"2023-09-12T00:36:27+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=59760"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=59760#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=59760","url":"https:\/\/ifintechworld.com\/?p=59760","name":"Crinetics shares surge after \"positive\" hormonal disorder drug trial results | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-09-12T00:36:24+00:00","dateModified":"2023-09-12T00:36:27+00:00","description":"\u00a9 Reuters. Investing.com --\u00a0Shares in Crinetics Pharmaceuticals (NASDAQ:) soared in early U.S. trading on Monday after the drugmaker announced the","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=59760#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=59760"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=59760#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Crinetics shares surge after “positive” hormonal disorder drug trial results"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/59760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59760"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/59760\/revisions"}],"predecessor-version":[{"id":59762,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/59760\/revisions\/59762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/59761"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}